Azilsartan description: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Azilsartan}} {{CMG}}; {{AE}} {{SS}} ==Description== Edarbi (azilsartan medoxomil), a prodrug, is hydrolyzed to azilsartan in the gastrointestinal tract during abs...")
 
 
Line 1: Line 1:
__NOTOC__
#REDIRECT [[Azilsartan kamedoxomil#Structure]]
{{Azilsartan}}
{{CMG}}; {{AE}} {{SS}}
 
==Description==
Edarbi (azilsartan medoxomil), a prodrug, is hydrolyzed to azilsartan in the gastrointestinal tract during absorption. Azilsartan is a selective AT1 subtype angiotensin II receptor antagonist.
 
The drug substance used in the drug product formulation is the potassium salt of azilsartan medoxomil, also known by the US accepted name of azilsartan kamedoxomil and is chemically described as (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate monopotassium salt.
 
Its empirical formula is C30H23KN4O8 and its structural formula is:
 
{|
|[[File:Azilsartan03.jpg|thumb|800px]]
|}
 
Azilsartan kamedoxomil is a white to nearly white powder with a molecular weight of 606.62. It is practically insoluble in water and freely soluble in methanol.
 
Edarbi is available for oral use as tablets. The tablets have a characteristic odor. Each Edarbi tablet contains 42.68 or 85.36 mg of azilsartan kamedoxomil, which is equivalent to containing 40 mg or 80 mg respectively, of azilsartan medoxomil and the following inactive ingredients: mannitol, fumaric acid, sodium hydroxide, hydroxypropyl cellulose, croscarmellose sodium, microcrystalline cellulose, and magnesium stearate.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = EDARBI (AZILSARTAN KAMEDOXOMIL) TABLET [TAKEDA PHARMACEUTICALS AMERICA, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=75b16bfc-38c1-4133-bd7d-13258d54edec | publisher =  | date =  | accessdate = 19 February 2014 }}</ref>
 
==References==
{{Reflist}}
 
[[Category:Angiotensin II receptor antagonists]]
[[Category:Benzimidazoles]]
[[Category:Carbamates]]
[[Category:Ethers]]
[[Category:Cardiovascular Drugs]]
[[Category:Drugs]]

Latest revision as of 03:08, 22 July 2014